Alnylam: Waiting For Regulatory Updates In March
Portfolio Pulse from
Alnylam is awaiting FDA decisions on Amvuttra and Sanofi's fitusiran, which could boost its revenue and profitability. Approvals are expected next month, potentially accelerating growth and generating royalties.
February 13, 2025 | 10:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alnylam is anticipating FDA approvals for Amvuttra and fitusiran, which could enhance revenue and profitability. Amvuttra's approval is expected to drive growth, while fitusiran could generate significant royalties.
The FDA approvals for Amvuttra and fitusiran are critical for Alnylam's revenue growth and profitability. Amvuttra's approval is expected to drive growth in 2025, while fitusiran could provide significant royalties from Sanofi.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
Sanofi's fitusiran, partnered with Alnylam, is awaiting FDA approval. Approval could lead to significant royalties for Alnylam, indirectly benefiting Sanofi's partnership.
While the direct financial impact is on Alnylam, Sanofi's partnership in fitusiran means its approval could enhance the collaboration's value, indirectly benefiting Sanofi.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 60